<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489329</url>
  </required_header>
  <id_info>
    <org_study_id>REB 20-1211</org_study_id>
    <nct_id>NCT04489329</nct_id>
  </id_info>
  <brief_title>Dietary Intervention Detection in the Small Intestine</brief_title>
  <official_title>Use of the Small Intestine Microbiome Aspiration (SIMBA) Capsule to Detect a Dietary Intervention in the Small Intestine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nimble Science Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nimble Science Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof of concept study to validate the ability of the ingestible capsule to gather samples
      from the small bowel for microbiome analysis in adults and to detect dietary changes from
      simultaneous ingestion of a probiotic.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial density count</measure>
    <time_frame>7 days</time_frame>
    <description>density count of probiotic strain compared between capsule and stool sample (CFU/ml)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Proof of Concept</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant swallows and retrieves capsule in stool before and after ingestion of a probiotic. Capsule and stool samples are analyzed for presence of probiotic strain and compared to baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ingestible Capsule</intervention_name>
    <description>Participants will swallow capsule and undergo X-rays to establish transit</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 65 years old

          2. Healthy

          3. On no medication, or on stable doses of medications which will not be changed over the
             course of the study

          4. Willingness to maintain their usual dietary habits and physical activity

          5. Willing to discontinue consumption of fermented foods or probiotics (such as kombucha,
             yogurts with live, active cultures, or probiotic supplements) for the duration of the
             study.

          6. Ability to understand and provide informed consent

          7. Ability and willingness to meet the required schedule and study tasks and
             interventions

          8. Willing to fast for at least 8 hours before the 2 intake visits (Visit 1 and Visit 2)

        Exclusion Criteria:

          1. History of a small intestine obstruction of symptoms of an intermittent small
             intestine obstruction (i.e., recurrent abdominal pain, distention, nausea and
             vomiting).

          2. Pregnant or breastfeeding or planning on becoming pregnant during study timeline.

          3. Use of other investigational product within 3 months of start of the study.

          4. Suffering from immune disorders or with possible immune deficient status

          5. Allergy to soy or milk.

          6. Prior gastrointestinal surgery which has altered the anatomy of the esophagus, stomach
             or small or large intestine (exceptions include appendectomy or cholecystectomy more
             than 3 months prior to enrollment).

          7. Use of any medications in the previous 7 days that could substantially alter
             gastrointestinal motor function (e.g. opioids, prokinetics, anticholinergics,
             laxatives), acidity (PPI, H2RA), or integrity (NSAIDs, oral steroids).

          8. Body Mass Index (BMI) &gt; 38.

          9. Previous history of gastric bezoar or gastroparesis.

         10. Any abdominal or pelvic surgery within the past 3 months.

         11. Known history of inflammatory bowel disease and/or Crohn's disease.

         12. History of diverticulitis, diverticular stricture, or other intestinal strictures.

         13. History of abdominal or pelvic radiotherapy.

         14. History of dysphagia, eosinophilic esophagitis, esophageal stricture, or other
             swallowing disorder.

         15. Cardiovascular, endocrine, renal or other chronic disease likely to affect motility.

         16. Colon cleansing prep for 1 month before the first visit, or during the study.

         17. Use of antibiotics, prebiotics, herbal supplements, or probiotics for 2 weeks before
             the first visit, or during the study.

         18. &lt; 2 bowel movements per week.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Andrews, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Wilsack, MSc</last_name>
    <phone>403 592 5045</phone>
    <email>lwilsack@ucalgary.ca</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

